Immunocore Holdings PLC (IMCR)
Immunocore Holdings plc is a healthcare company whose American depositary receipt is listed on NASDAQ under the symbol IMCR. Through itself and its subsidiaries, the company develops and commercializes immunomodulating medicines for cancer, infectious diseases, and autoimmune disorders across the United States, Europe, and other international markets. Its commercial product is KIMMTRAK, used to treat unresectable or metastatic uveal melanoma. Immunocore also maintains a pipeline spanning multiple stages of development, including tebentafusp, brenetafusp, IMC-R117C, IMC-P115C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, with programs targeting oncology, HIV, hepatitis B, type 1 diabetes, and atopic dermatitis. Founded in 1999, the company is headquartered in Abingdon, United Kingdom.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IMCR
|
$39.71
|
16.1% Upside
|
Fair
|
$63.37
|
85.3% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-62.8x
|
4.4x
|
4.2x
|
1.732 B
|
1.323 B
|
20.1%
|
83.5%
|
6.0
|
—
|
111.5%
|
